Goldman Sachs is in the spotlight as tech firms Arm and Instacart test IPO market

Brasil Notícia Notícia

Goldman Sachs is in the spotlight as tech firms Arm and Instacart test IPO market
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 NBCNewYork
  • ⏱ Reading Time:
  • 13 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 63%

The drought in tech IPOs the past 18 months is about to break — and it’s a key moment for leading advisor Goldman Sachs.

initially to the roughly $55 billion that represents the top end of a target share price of $47 to $51.

Further, Arm is selling an unusually small slice of its overall stock, about 9%, which helps drive scarcity. That small public float means new investors will have fewer rights related to voting power and corporate governance, Trainer noted.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

NBCNewYork /  🏆 270. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Can Arm and Instacart Resuscitate the IPO Market?Can Arm and Instacart Resuscitate the IPO Market?Stocks Analysis by Christine Short covering: Campbell Soup Company, Hostess Brands Inc, Klaviyo Inc. Read Christine Short's latest article on Investing.com
Consulte Mais informação »

Goldman Sachs is in the spotlight as tech firms test IPO marketGoldman Sachs is in the spotlight as tech firms test IPO marketThe drought in tech IPOs the past 18 months is about to break — and it’s a key moment for leading advisor Goldman Sachs.
Consulte Mais informação »

Goldman Sachs asset and wealth management executive to retire, as others join firmGoldman Sachs asset and wealth management executive to retire, as others join firmGoldman Sachs Group Inc. executive Laurence Stein is retiring after 27 years at the bank, according to an internal memo seen by MarketWatch. Stein was most...
Consulte Mais informação »

Goldman Sachs discloses short position in Philips after Dutch regulator review By ReutersGoldman Sachs discloses short position in Philips after Dutch regulator review By ReutersGoldman Sachs discloses short position in Philips after Dutch regulator review
Consulte Mais informação »

Hedge funds have bailed on the U.S. consumer in a big way, Goldman Sachs data findsHedge funds have bailed on the U.S. consumer in a big way, Goldman Sachs data findsHedge funds are betting that the U.S. consumer is in for a difficult ride.
Consulte Mais informação »

Goldman Sachs says this blood cancer treatment stock can gain 70% ahead of planned drug launchGoldman Sachs says this blood cancer treatment stock can gain 70% ahead of planned drug launchAnalyst Corinne Jenkins upgraded the firm to buy from neutral and maintained her price target of $4.
Consulte Mais informação »



Render Time: 2025-02-26 14:55:40